Aigen Investment Management’s Vir Biotechnology VIR Stock Holding History

Aigen Investment Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$181K	Buy	20,249 +7,614	+60%	+$60.7K	0.05%	437
2025 Q4	$76.2K	Buy	+12,635	New	+$75.2K	0.02%	523
2025 Q2	–	Sell	-17,155	Closed	-$111K	–	1088
2025 Q1	$111K	Buy	+17,155	New	+$153K	0.02%	683
2024 Q3	–	Sell	-19,224	Closed	-$171K	–	1034
2024 Q2	$171K	Buy	+19,224	New	+$184K	0.03%	640
2023 Q4	–	Sell	-19,427	Closed	-$182K	–	1110
2023 Q3	$182K	Buy	+19,427	New	+$277K	0.03%	688
2022 Q1	–	Sell	-9,174	Closed	-$418K	–	1112
2021 Q4	$418K	Buy	+9,174	New	+$359K	0.03%	685

Other funds holding VIR

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.66B AUM 340.85% 1-Year Est. Return